The costs to the U.S. health care system of extending marketing exclusivity for Taxolρ

Journal of Research in Pharmaceutical Economics

Volumn 9, Issue 4, 1998, Pages 21-41

  Rozek, Richard P ^a   Berkowitz, Ruth ^a  

^a NERA ECONOMIC CONSULTING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; COLESTYRAMINE; ESTRADIOL; ETOPOFOS; ETOPOSIDE; GENERIC DRUG; GLIBENCLAMIDE; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; HYDROXYUREA; MEGESTROL ACETATE; MITOMYCIN C; PACLITAXEL; PROCAINAMIDE; SELEGILINE; SUCRALFATE; TOPOSAR; UNCLASSIFIED DRUG;

DRUG APPROVAL; DRUG COST; DRUG MARKETING; LAW; PRIORITY JOURNAL; REVIEW; TAX; TRANSDERMAL PATCH; UNITED STATES;

EID: 0032323812     PISSN: 08966621     EISSN: None     Source Type: Journal    
DOI: 10.1300/J063v09n04_02     Document Type: Review

References (27)

1. Nicolau KC, Guy R, Potier P. Taxoids: new weapons against cancer. Scientific Am 1996;274(6):94-8.
2. Lonning P. Paclitaxel and docetaxel: Innovation, but at what cost? PharmacoEconomics 1995;8(1):1-4.
3. Bristol-Myers Squibb Taxol® refractory breast cancer approval. Pink Sheet 1994;(Apr 18):T&G-1.
4. Bristol/NCI Taxol agreement worth up to $30 mil. per year. Pink Sheet 1996;(Dec 16):T&G-4.
5. Demonstration project to fund biomedical research. Proposed legislation to the Fiscal Year 1998 Labor, Health and Human Services, and Education Appropriations Bill.
6. PDR generics. 2nd ed. Montvale, NJ: Medical Economics, 1996.
7. VHA/Bristol private label taxol deal to build market loyalty. Pink Sheet 1997; (Feb24):T&G-14.
8. Bergen would compete with Bristol on oncology market after IVAX merger: firms already compete in oncology distribution; IVAX expands Glaxo inhaler deal. Pink Sheet 1996;(Nov 18):13.
9. IVAX unit gets tentative FDA OK for Kaposi's sarcoma drug. Standard & Poors, 1997, http://biz.yahoo.com/snp/971229/npro_drg_npp_1.html.
10. Citizen petition filed on behalf of Oregon Natural Resources Council with the FDA, January 3, 1997:10-11.
11. President's Letter. Annual report to the shareholders. Cytoclonal Pharmaceutics Inc., Disclosure Incorporated, 1997.
12. ChiRex/InNova ANDA to be filed in first half of 1996. Pink Sheet 1996; (Mar 18):T&G-4.
13. Grabowski H, Vernon J. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 drug act. J Law Econ 1992:331-50.
14. Caves RE, Whinston MD, Hurwitz MA. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers Econ Activity Microecon 1991:1-48.
15. Drug Topics red book. Montvale, NJ: Medical Economics, 1996.
16. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manage Strategy 1997;6(1):75-90.
17. Thwaite EW. Beat the generics by joining them. Med Market Media 1992; 27(Sept):110.
18. Dillon Read equity research industry report. March 8, 1995:21.
19. IVAX gets an initial OK for a new drug. Miami Herald 1997 Sept 20.
20. AWP overstates actual pharmacy invoice cost for brand name drugs by average of 18.3% nationwide, HHG concludes; generic AWP overstates cost by 42.5%. Pink Sheet 1997;(Jan 13):7.
21. Taxol acquisition costs range from 14.9%-23.2% below AWP. Pink Sheet 1997; (Dec 15):T&G-8.
22. U.S. General Accounting Office. Reimbursement policies for off-label drugs. GAO/PEND-91-14. September 27, 1991:33.
23. Bristol-Myers Squibb Company (BMY). Alex. Brown. November 13, 1996:5.
24. Pharma pipelines: new product timelines for the pharmaceutical industry. Lehman Brothers. January 1996:B38.
25. Treasury bonds, notes & bills. Wall Street J 1997 Feb 25:C22.
26. U.S. Department of Health and Human Services. Office of the Inspector General. Appropriateness of Medicare prescription drug allowances. OEI-03-95-00420. May 1996.
27. Fax from Karen Beebe, Health Care Financing Administration, to Ruth Berkowitz, March 10, 1997.